Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by priceless2on Jan 26, 2014 2:48pm

133 Views

Post# 22135412

RE:RE:RE:Here's an idea....let's talk about the company and the stock

Jd, one must not forget that Ken DArt investment in rvx is still long and strong, and he was even willing to pay a premium in sp in his last pp at .90 this past sept He obviously is very long and strong in his investment in rvx and I will ride his coattail all day long. As long as he still involved have strong faith not only in the science but managements decision how to move this forward to goal line even if there is some minimal dilution to get us there.

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects